Mark Bolton: What if patients switch treatment at progression
Mark Bolton, Radiation Oncologist, shared a post on X, about a paper by Amani Al Tawil et al. published in BMC Medical Research Methodology.
“Re-analysis of RCT with e.g. IPCW vs sticking with ITT.
‘Far better an approximate answer to the right question, which is often vague, than the exact answer to the wrong question, which can always be made precise.’
So what if patients switch treatment at progression?
What decision-maker is interested in this?
With parametric g-formula and IPCW, estimates are all over the place depending on model specification etc, and result in a much worse alternative than ITT
I don’t understand this type of work.”
Pavlos Msaouel, Assistant Professor of Genitourinary Medical Oncology at MD Anderson Cancer Center, shared this post, adding:
“So great to see oncology finally addressing these issues. It will take work to define consensus strategies but this is a step in the right direction. See recent Kidney Cancer overview and statement on the topic.”
Authors: Amani Al Tawil, Sean McGrath, Robin Ristl, Ulrich Mansmann.
More posts featuring Pavlos Msaouel.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023